Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.37 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4380801 | 0.87 | KDM4E (0.38) | LMNAMAPTCNR2LTB4RLTB4R2 | |
| SCHEMBL4384668 | 0.86 | NR4A2 (0.39) | NPSR1LMNAMAPTSMN1; SMN2TDP1 | |
| SCHEMBL4393895 | 0.85 | LMNA (0.48) | NPSR1LMNASMN1; SMN2HTTKMT2A | |
| SCHEMBL4396687 | 0.82 | PTGFR (0.46) | LMNAMAPTTDP1KMT2AMEN1 | |
| SCHEMBL4381538 | 0.79 | CNR2 (0.38) | LMNAMAPTSMN1; SMN2CNR2HTT | |
| SCHEMBL4380223 | 0.79 | SMN1; SMN2 (0.42) | LMNAMAPTSMN1; SMN2TDP1CNR2 | |
| SCHEMBL4394879 | 0.78 | HPGD (0.44) | NPSR1LMNASMN1; SMN2CNR2KMT2A | |
| SCHEMBL4382263 | 0.77 | MAPT (0.47) | LMNAMAPTALDH1A1 | |
| SCHEMBL4388905 | 0.77 | HPGD (0.37) | LMNAMAPTCNR2HTTKMT2A | |
| SCHEMBL4392444 | 0.76 | PLA2G2A (0.41) | MAPTCNR2HTTGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538241-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20070155813-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| EP-1704856-A1 | HSP90 FAMILY PROTEIN INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155813-A1 | Hsp90 family protein inhibitors | HSP90AB1, HEATR1, HSP90AB2P | NPSR1 331/4885LMNA 4706/4885MAPT 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.